{"title":"Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis.","authors":"Jian-Xing Luo, Guo Chen, Xiao-Yu Hu, Chang Yu","doi":"10.1016/j.gastrohep.2024.502276","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.</p><p><strong>Methods: </strong>MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.</p><p><strong>Results: </strong>24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.</p><p><strong>Conclusions: </strong>TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologia y hepatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gastrohep.2024.502276","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.
Methods: MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.
Results: 24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.
Conclusions: TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.
背景：TAF 和 ETV 之间的优劣仍不明确。哪种方法是 CHB 患者的最佳选择？因此，本荟萃分析旨在评估 TAF 和 ETV 对 CHB 患者的疗效和安全性：方法：检索了MEDLINE/PubMed、Cochrane图书馆、EMBASE、Web of Science和CNKI，寻找从开始到2024年1月符合条件的研究，并进行了荟萃分析。与ETV相比，TAF能明显改善12周和24周完全病毒学应答（CVR）、12周生化应答（BR）和24周HBeAg丢失，但不能改善48周和96周CVR、24周、48周和96周BR、96周HBeAg丢失、不良事件、48周HBsAg下降和丢失、12周、24周和48周HBeAg血清转换、96周HCC发生率。根据种族、研究类型和转换进行了亚组分析。不同的亚组得出了不同的结果：结论：在12周和24周CVR、12周BR和24周HBeAg丢失方面，TAF优于ETV。种族和转换可能会影响 TAF 和 ETV 的疗效。
期刊介绍：
Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
